These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1288 related items for PubMed ID: 11074658

  • 1. Antitumor vaccination: where we stand.
    Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.
    Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
    [Abstract] [Full Text] [Related]

  • 2. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA, Neelapu SS, Kwak LW, Biragyn A.
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [Abstract] [Full Text] [Related]

  • 3. Cell therapy: achievements and perspectives.
    Bordignon C, Carlo-Stella C, Colombo MP, De Vincentiis A, Lanata L, Lemoli RM, Locatelli F, Olivieri A, Rondelli D, Zanon P, Tura S.
    Haematologica; 1999 Dec; 84(12):1110-49. PubMed ID: 10586214
    [Abstract] [Full Text] [Related]

  • 4. Ex vivo expansion of hematopoietic cells and their clinical use.
    Aglietta M, Bertolini F, Carlo-Stella C, De Vincentiis A, Lanata L, Lemoli RM, Olivieri A, Siena S, Zanon P, Tura S.
    Haematologica; 1998 Sep; 83(9):824-48. PubMed ID: 9825579
    [Abstract] [Full Text] [Related]

  • 5. Genetically modified tumour vaccines--where we are today.
    Nawrocki S, Mackiewicz A.
    Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588
    [Abstract] [Full Text] [Related]

  • 6. Clinical use of allogeneic hematopoietic stem cells from sources other than bone marrow.
    Arcese W, Aversa F, Bandini G, De Vincentiis A, Falda M, Lanata L, Lemoli RM, Locatelli F, Majolino I, Zanon P, Tura S.
    Haematologica; 1998 Feb; 83(2):159-82. PubMed ID: 9549928
    [Abstract] [Full Text] [Related]

  • 7. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE.
    Oncol Rep; 2002 Feb; 9(2):267-76. PubMed ID: 11836591
    [Abstract] [Full Text] [Related]

  • 8. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic hematopoietic stem cells from sources other than bone marrow: biological and technical aspects.
    Bertolini F, de Vincentiis A, Lanata L, Lemoli RM, Maccario R, Majolino I, Ponchio L, Rondelli D, Tabilio A, Zanon P, Tura S.
    Haematologica; 1997 Aug; 82(2):220-38. PubMed ID: 9175330
    [Abstract] [Full Text] [Related]

  • 10. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 12. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D, Moyana T, Xiang J.
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [Abstract] [Full Text] [Related]

  • 13. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA, Hu P, Epstein AL.
    Handb Exp Pharmacol; 2008 Mar; (181):291-328. PubMed ID: 18071951
    [Abstract] [Full Text] [Related]

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 15. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N, Andreesen R, Mackensen A.
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [Abstract] [Full Text] [Related]

  • 16. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [Abstract] [Full Text] [Related]

  • 17. Genetically engineered dendritic cell-based cancer vaccines (review).
    Bubeník J.
    Int J Oncol; 2001 Mar; 18(3):475-8. PubMed ID: 11179474
    [Abstract] [Full Text] [Related]

  • 18. Modulation of antitumor immune responses by hematopoietic cytokines.
    Waller EK, Ernstoff MS.
    Cancer; 2003 Apr 01; 97(7):1797-809. PubMed ID: 12655538
    [Abstract] [Full Text] [Related]

  • 19. Vaccination: role in metastatic melanoma.
    Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M, Parmiani G, Rivoltini L.
    Expert Rev Anticancer Ther; 2006 Aug 01; 6(8):1305-18. PubMed ID: 16925496
    [Abstract] [Full Text] [Related]

  • 20. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS.
    Anticancer Res; 2003 Aug 01; 23(3A):1969-96. PubMed ID: 12894571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.